BRIEF published on 07/30/2026 at 21:54, 2 months 1 day ago Ikonisys SA announces promising annual results for 2025 Financial Results Growth Ikonisys ALIKO SCIENTIFIC Oncological Diagnosis
BRIEF published on 07/30/2026 at 21:54, 2 months 1 day ago Ikonisys SA annonce une augmentation de son chiffre d'affaires et des développements en 2025 Ikonisys SA Croissance Des Revenus Résultats Financiers 2025 Diagnostic En Oncologie Aliko Scientifique
BRIEF published on 07/30/2026 at 21:54, 2 months 1 day ago Ikonisys SA annonce des résultats annuels 2025 prometteurs Résultats Financiers Croissance Ikonisys Diagnostic Oncologique ALIKO SCIENTIFIC
BRIEF published on 07/30/2026 at 21:54, 2 months 1 day ago Ikonisys SA Reports Increased Revenues and Developments in 2025 Revenue Growth Ikonisys SA Oncology Diagnostics ALIKO SCIENTIFIC Financial Results 2025
PRESS RELEASE published on 07/30/2026 at 21:49, 2 months 1 day ago Informations privilégiées / Communiqué sur comptes, résultats Ikonisys SA publie ses résultats financiers annuels 2025. Amélioration de 32,9% de l'EBITDA à -1,14 M€. Développement de la plateforme oncologique avec brevet ACTA, Urine24 et accord Menarini Diagnostics Résultats Financiers EBITDA Ikonisys SA Développements Plateforme Oncologique
PRESS RELEASE published on 07/30/2026 at 21:49, 2 months 1 day ago Inside Information / News release on accounts, results Aliko Scientific (Ikonisys SA) reports 52.6% increase in total revenue to €1.64 million and 32.9% improvement in EBITDA for 2025. Developments include US patent for ACTA, launch of Urine24, and agreement with Menarini Diagnostics Financial Results Revenue Increase EBITDA Improvement Oncology Diagnostics ALIKO SCIENTIFIC
BRIEF published on 07/23/2026 at 07:35, 2 months 8 days ago Hospitex International initiates a feasibility study in Uzbekistan for Urine24 Feasibility Study Hospitex International Uzbekistan Urine24 Oncological Diagnoses
BRIEF published on 07/23/2026 at 07:35, 2 months 8 days ago Hospitex International initie une étude de faisabilité en Ouzbékistan pour Urine24 Étude De Faisabilité Hospitex International Ouzbékistan Diagnostics Oncologiques Urine24
BRIEF published on 07/23/2026 at 07:35, 2 months 8 days ago Hospitex International Initiates Urine24 Feasibility Study in Uzbekistan Feasibility Study Cancer Diagnostics Hospitex International Urine24 Uzbek Oncology Institute
BRIEF published on 07/23/2026 at 07:35, 2 months 8 days ago Hospitex International lance une étude de faisabilité sur Urine24 en Ouzbékistan Étude De Faisabilité Hospitex International Diagnostic Du Cancer Urine24 Institut D'oncologie Ouzbek
Published on 10/01/2026 at 01:21, 3 hours 33 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 3 hours 54 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 5 hours 24 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 8 hours 19 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 09/30/2026 at 15:50, 13 hours 4 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 23:23, 5 hours 31 minutes ago LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance
Published on 09/30/2026 at 22:34, 6 hours 20 minutes ago The Change of Date of the Annual Report 2025 Publication
Published on 09/30/2026 at 22:05, 6 hours 49 minutes ago ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model
Published on 09/30/2026 at 22:05, 6 hours 49 minutes ago Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Published on 09/30/2026 at 22:05, 6 hours 49 minutes ago Abivax présentera des données sur l’obéfazimod lors de l’United European Gastroenterology (UEG) Week 2026
Published on 09/30/2026 at 18:44, 10 hours 10 minutes ago Broadcast of the 5th edition of “On the way up”
Published on 09/30/2026 at 18:44, 10 hours 10 minutes ago Diffusion de la 5e édition de “On the way up”
Published on 09/30/2026 at 18:18, 10 hours 36 minutes ago Nombre total de droits de vote et d'actions composant le capital social
Published on 09/30/2026 at 18:15, 10 hours 39 minutes ago The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:15, 10 hours 39 minutes ago L’État belge et le groupe ENGIE ont convenu de reporter au 4 novembre 2026 la date cible pour la conclusion des Heads of Terms
